Diseases of the cornea and ocular surface – an optimal management Review article

Article Sidebar

PDF PDF (Język Polski)


Published: Dec 31, 2024
DOI: https://doi.org/10.24292/01.OT.011224
Keywords:
ocular surface, cornea, ocular surface disease, dry eye disease, dexpanthenol

Main Article Content

Monika Udziela
1. Chair and Department of Ophthalmology, Faculty of Medicine, Medical University of Warsaw. 2. Independent Public Clinical Ophthalmology Hospital in Warsaw.
https://orcid.org/0000-0001-5036-2091

Abstract

The ocular surface diseases including dry eye disease are still increasing issue worldwide. Mild disorders are not sight threatening, but in advanced stages they may lead to serious complications. In some cases the treatment itself is the main cause for developing or aggravation of the dry eye disease, especially in patients with risk factors. The exact examination allows to avoid the misdiagnosis and to choose the optimal management.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Udziela M. Diseases of the cornea and ocular surface – an optimal management. Ophthatherapy [Internet]. 2024Dec.31 [cited 2025May14];11(4):374-8. Available from: https://journalsmededu.pl/index.php/ophthatherapy/article/view/3237
Issue
Vol 11 No 4 (2024)
Section
Conservative treatment

Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Aragona P, Rolando M. Towards a dynamic customised therapy for ocular surface dysfunctions. Br J Ophthalmol. 2013; 97(8): 955-60.
2. Willcox MDP, Argüeso P, Georgiev GA et al. TFOS DEWS II tear film report. Ocul Surf. 2017; 15(3): 366-403.
3. Craig JP, Nichols KK, Akpek EK et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017; 15(3): 276-83.
4. Singh S, Das AV, Basu S. Ocular involvement in Sjögren syndrome: risk factors for severe visual impairment and vision-threatening corneal complications. Am J Ophthalmol. 2021; 225: 11-7.
5. Stapleton F, Alves M, Bunya VY et al. TFOS DEWS II Epidemiology Report. Ocul Surf. 2017; 15(3): 334-65.
6. Craig JP, Alves M, Wolffsohn JS et al. TFOS Lifestyle Report Executive Summary: A Lifestyle Epidemic - Ocular Surface Disease. Ocul Surf. 2023; 30: 240-53.
7. Gomes JAP, Azar DT, Baudouin C et al. TFOS DEWS II iatrogenic report. Ocul Surf. 2017; 15(3): 511-38.
8. Mencucci R, Vignapiano R, Rubino P et al. Iatrogenic Dry Eye Disease: Dealing with the Conundrum of Post-Cataract Discomfort. A P.I.C.A.S.S.O. Board Narrative Review. Ophthalmol Ther. 2021; 10(2): 211-23.
9. Mastropasqua L, Barboni P, Savini G et al. Refractive surgery and dry eye. Eur J Ophthalmol. 2023 May 22: 11206721231176312.
10. Zhao PF, Zhou YH, Hu YB et al. Evaluation of preoperative dry eye in people undergoing corneal refractive surgery to correct myopia. Int J Ophthalmol. 2021; 14(7): 1047-51.
11. Jones L, Downie LE, Korb D et al. TFOS DEWS II Management and Therapy Report. Ocul Surf. 2017; 15(3): 575-628.
12. Raczyńska K, Iwaszkiewicz-Bilikiewicz B, Stozkowska W et al. Clinical evaluation of provitamin B5 drops and gel for postoperative treatment of corneal and conjuctival injuries. Klin Oczna. 2003; 105(3-4): 175-8.